Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT-2: LA-EP2006 vs Neulasta in breast cancer
NCT01516736Phase 3Completed
- Sponsor
- Sandoz
- Start
- Mar 2012
- Primary completion
- Aug 2013
- Modality
- Cytokines & Interferons
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of pegfilgrastim-bmez in chemotherapy-induced neutropenia (CIN) (2 arms), sponsored by Sandoz. Primary endpoint: Mean Duration of Severe Neutropenia During Cycle 1 at 21 days. Started Mar 2012; status: completed.
02
Drugs
pegfilgrastim-bmez
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT01516736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01516736.